Drilldown/Medicines
Use the filters below to narrow your results.
generic:
25B-NBOH (1) ·
25B-NBOMe (1) ·
25C-NBOH (1) ·
25C-NBOMe (1) ·
25I-NBOH (1) ·
25I-NBOMe (1) ·
25N-NBOMe (1) ·
2C-B (1) ·
2C-B-FLY (1) ·
2C-C (1) ·
2C-D (1) ·
2C-E (1) ·
2C-I (1) ·
2C-P (1) ·
2C-T-2 (1) ·
2C-T-7 (1) ·
Allylescaline (1) ·
Bromo-DragonFLY (1) ·
DOB (1) ·
DOC (1) ·
DOI (1) ·
DOM (1) ·
Escaline (1) ·
Lisdexamfetamine (dimesylate) (1) ·
Methallylescaline (1) ·
Modafinil (1) ·
Proscaline (1) ·
TMA-2 (1)
brand:
None (25) ·
Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) ·
Provigil (US, 100 mg and 200 mg tablets); Alertec (Canada); Modiodal (France, original market). See also: Armodafinil (Nuvigil), the R-enantiomer, a related eugeroic approved 2007 with a longer effective half-life. (1) ·
Vyvanse, Elvanse (EU) (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (12) ·
5-HT2A agonist; long duration (1) ·
5-HT2A agonist; MAO inhibitor (1) ·
5-HT2A agonist; milder than other 2C-x (1) ·
5-HT2A partial agonist (1) ·
Extremely potent 5-HT2A agonist; vasoconstrictor (1) ·
Extremely potent 5-HT2A agonist; very long duration (1) ·
Potent 5-HT2A agonist (5) ·
Potent 5-HT2A agonist; no oral activity (1) ·
Potent 5-HT2A agonist; very long duration (1) ·
Very potent 5-HT2A agonist; long duration (1) ·
'"`UNIQ--vote-00000013-QINU`"' Once converted, dextroamphetamine acts by displacing dopamine and norepinephrine from presynaptic vesicles via VMAT-2 and reversing DAT and NET transport, the shared mechanism of all amphetamine-class agents'"`UNIQ--ref-00000014-QINU`"'. (1) ·
'"`UNIQ--vote-00000049-QINU`"' (1)
starting dose:
None (26) ·
ADHD: 30 mg PO once daily in the morning; titrate by 10-20 mg weekly to clinical effect. Binge-eating disorder: 30 mg/day, titrate to 50-70 mg/day (1) ·
Narcolepsy/OSA: 200 mg PO once daily in the morning. Shift work disorder: 200 mg PO approximately 1 hour before the start of the work shift. Lower starting dose (100 mg) can be considered in elderly patients or those with hepatic impairment. (1)
preparations:
fda max:
routes:
onset:
None (25) ·
1-2 hours (slower than immediate-release amphetamine because activation requires enzymatic cleavage in red blood cells) (1) ·
45-75 min (oral) (1) ·
Peak plasma concentrations 2-4 hours after oral dose. Wakefulness-promoting effect onset correlates with peak plasma; subjective alertness typically reported within 1-2 hours of dosing. (1)
duration:
None (25) ·
10-12 hours (smoother profile than immediate-release amphetamine salts) (1) ·
4-8 h (1) ·
Effective wakefulness promotion through approximately 12-15 hours reflecting the half-life of the predominant R-enantiomer. For shift-work use, 200 mg taken 1 hour before shift provides coverage through most 8-12 hour shifts. (1)
halflife:
bioavailability:
None (25) ·
Approximately 80% (well-absorbed orally; not significantly affected by food, though food may delay Tmax by ~1 hour).'"`UNIQ--ref-0000004D-QINU`"' (1) ·
Not well characterized (1) ·
~96% after red blood cell hydrolytic cleavage releases dextroamphetamine'"`UNIQ--ref-00000018-QINU`"' (1)
pregnancy:
Showing below up to 28 results in range #1 to #28.